Zivo Bioscience Inc. has entered into a separation and release agreement with outgoing Chief Financial Officer Keith R. Marchiando, who will receive his current monthly salary of $27,040 until December 31, 2026. Marchiando will also retain a previously awarded option to acquire 150,000 shares of the company’s common stock at an exercise price of $7.96 per share, exercisable until June 30, 2027. The agreement includes provisions related to release of claims, confidentiality, and non-disparagement.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zivo Bioscience Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001654954-25-014296), on December 23, 2025, and is solely responsible for the information contained therein.